Document ID: FDA-2013-N-0001-0055
Agency: fda
Document Type: Notice
Title: Joint Meeting of the Risk Communication Advisory Committee and Tobacco Products Scientific Advisory Committee; Notice of Joint Meeting
Posted Date: 2013-06-24T04:00Z

[Federal Register Volume 78, Number 121 (Monday, June 24, 2013)]
[Notices]
[Page 37821]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14947]

[[Page 37821]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0001]

Joint Meeting of the Risk Communication Advisory Committee and 
Tobacco Products Scientific Advisory Committee; Notice of Joint Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Risk Communication Advisory Committee and 
Tobacco Products Scientific Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.

DATES: Date and Time: The meeting will be held on August 15, 2013 from 
9 a.m. to 5 p.m.

ADDRESSES: Food and Drug Administration, White Oak Campus.
    Location: FDA White Oak Conference Center, Bldg. 31, Rm. 1503, 
10903 New Hampshire Ave., Silver Spring, MD 20993-0002. Information 
regarding special accommodations due to a disability, visitor parking, 
and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/default.htm; under the heading ``Resources for 
You,'' click on ``Public Meetings at the FDA White Oak Campus.'' Please 
note that visitors to the White Oak Campus must enter through Building 
1.
    Contact Person: Luis G. Bravo, Designated Federal Official, 10903 
New Hampshire Ave., Bldg. 32, Rm. 3274, Silver Spring, MD 20993, 1-877-
287-1373 (choose option 5), email: RCAC@fda.hhs.gov, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), to find out further information regarding FDA 
advisory committee information. A notice in the Federal Register about 
last minute modifications that impact a previously announced advisory 
committee meeting cannot always be published quickly enough to provide 
timely notice. Therefore, you should always check the Agency's Web site 
at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to 
the appropriate advisory committee meeting link, or call the advisory 
committee information line to learn about possible modifications before 
coming to the meeting.
    Agenda: The Federal Food, Drug & Cosmetic Act (the FD&C Act) 
requires tobacco product manufacturers and importers to report 
quantities of harmful and potentially harmful constituents (HPHCs) in 
tobacco products or tobacco smoke by brand and subbrand. The FD&C Act 
also requires the Agency to publish a list of HPHCs by brand and by 
quantity in each brand and subbrand by April of 2013, in a format that 
is understandable and not misleading to the layperson.
    On August 15, 2013, the Committees will meet in joint session to 
discuss the results of the FDA consumer research ``Experimental Study 
on the Public Display of Lists of Harmful and Potential Harmful Tobacco 
Constituents'' [OMB Control No. 0910-0736] to assess the impact of HPHC 
information on consumer perceptions and comprehension, and how to 
effectively communicate information about the HPHCs of tobacco products 
to the general public.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
August 1, 2013. Oral presentations from the public will be scheduled 
between approximately 1 p.m. and 2 p.m. Those individuals interested in 
making formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before July 25, 2013. Time allotted for 
each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by July 26, 2013. Interested persons can also 
log on to https://collaboration.fda.gov/rcac/ to hear and see the 
proceedings.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Luis G. Bravo at 
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: June 18, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2013-14947 Filed 6-21-13; 8:45 am]
BILLING CODE 4160-01-P